aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ... aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
8 igulisxmeba piri, romelsac aReniSneba poliomielitis vaqcinis virusis gadacemis riski aiv inficirebul pirze fekaluri an oraluri gziT. rekomendacia • pov ar unda iqnas gamoyenebuli aiv inficirebul/SidsiT daavadebulebSi, rogorc bavSvebSi, aseve zrdasrulebSi, imunodeficitis statusis miuxedavad; aseve maTi ojaxis wevrebsa da maTTan mWidro kontaqtSi myof sxva pirebSi (AI). 4.2.5. rotavirusis vaqcina rekomendacia • Semdgomi samecniero mtkicebulebebiT aiv inficirebul bavSvebSi vaqcinis usafrTxoebisa da imunogenurobis profilis dadasturebamde aRniSnul kategoriaSi rotavirusis vaqcina ar unda iqnas gamoyenebuli damoukideblad imunodeficitis statusisa (CIII). 4.2.6. muclis tifis (Ty21a) vaqcina miuxedavad imisa, rom asimptomur aiv inficirebul pirebs 200/mm 3 -ze maRali CD4+ limfocitebis absoluturi ricxviT SesaZlebelia CautardeT vaqcinacia muclis tifis cocxali atenuirebuli vaqciniT (Ty21a jaWvis gamoyenebiT), parenteraluri inaqtivirebuli vaqcina Teoriulad ufro usafrTxo alternativaa (DIV). rekomendacia • Ty21a vaqcina ar unda iqnas gamoyenebuli aiv inficirebul/SidsiT daavadebulebSi, rogorc bavSvebSi, aseve zrdasrulebSi, imunodeficitis statusis miuxedavad. 4.2.7. Cutyvavilas vaqcina miuxedavad imisa, rom mcire zomis axalma kvlevam ar gamoavlina mniSvnelovani gverdiTi reaqciebi 10 aiv inficirebul bavSvSi, aiv infeqcia/SidsiT gamowveuli zomieri an mZime imunodeficitis mqone pirebs Cutyvavilas vaqciniT vaqcinacia ar unda CautardeT. Tumca asimptomur da msubuqad gamoxatuli simptomatikis mqone aiv inficirebul bavSvebs, romelTa CD4 ujredebis ricxvi 25% an metia pirveli vaqcinacia unda CautardeT 12-15 Tvis asakSi, xolo ganmeorebiTi 4-8 kviris Semdeg. virusuli infeqciis SesaZlo diseminaciis gamo Cutyvavilas vaqcina ar unda iqnas gamoyenebuli im aiv inficirebul bavSvebSi, romelTa CD4 ujredebis ricxvi 25%-ze naklebia. aiv inficirebuli bavSvebi da mozrdilebi, romlebic gamoirCevian maRali mimReblobiT Cutyvavila-zosteris virusis mimarT _ pirebi, 114
omlebsac ar gadautaniaT Cutyvavila (pirveladi infeqcia), aReniSnebaT zosteri (rekurentuli infeqcia) an arian seronegatiurni _ sasurvelia moeridon eqspozicias CutyvaviliT an zosteriT daavadebul pirebTan. aiv inficirebul/SidsiT daavadebulebTan mWidro kontaqtSi myof pirebs (gansakuTrebiT bavSvebs), romlebsac ar gadautaniaT Cutyvavila da arian aiv seronegatiurebi, unda CautardeT Cutyvavilas vaqcinacia, raTa ar moxdes virusis transmisia am pirebidan im aiv inficirebulebze, romlebic Cutyvavila-zosteris virusis mimarT maRali mimReblobiT gamoirCevian. rekomendaciebi • Cutyvavilas vaqcina ar unda iqnas gamoyenebuli aiv inficirebul mozrdilebSi imunodeficitis statusis miuxedavad, aseve aiv inficirebul bavSvebSi zomieri an mZime imunosupresiiT. • Cutyvavilas vaqcina unda gamoviyenoT mxolod asimptomur da msubuqad gamoxatuli simptomatikis mqone aiv inficirebul bavSvebSi (CD4>=25%) (BII). • aiv inficirebul/SidsiT daavadebulebTan mWidro kontaqtSi myof pirebs, romlebic gamoirCevian virusis mimarT maRali mimReblobiT, unda CautardeT vaqcinacia Cutyvavila-zosteris virusis SesaZlo transmisiis prevenciis mizniT. 4.2.8. yviTeli cxelebis vaqcina yviTeli cxelebis vaqcinis virusi Teoriulad warmoadgens encefalitis ganviTarebis risk-faqtors aiv inficirebul pirebSi, ris gamoc is aRniSnul kategoriaSi ar gamoiyeneba. yviTeli cxeleba endemuri daavadebaa ekvatoruli afrikis 33 da samxreT amerikis 11 qveyanaSi. aRniSnul teriatoriaze mogzaurobisas mkurnalma eqimma pacients unda miawodos informacia arsebuli riskisa da moskitebisagan Tavdacvis meTodebis Sesaxeb. zogierTi klinika pirovnebis CD4+ ujredebis ricxvis gaTvaliswinebiT iRebs vaqcinaciis gadawyvetilebas. Tu aiv inficirebuli piri ver aridebs Tavs yviTeli cxelebis virusTan potenciur eqspozicias mas unda SevTavazoT vaqcinacia. saWiroa vaqcinaciasTan dakavSirebuli SesaZlo gverdiTi reaqciebis monitoringi. ramdenadac aiv negatiur pirebTan SedarebiT aiv pozitiur adamianebSi vaqcinacia SesaZloa iyos naklebad efeqturi, sasurvelia maneitralizebeli antisxeulebis titris gansazRvra endemur keraSi mogzaurobamde. yviTeli cxelebis sawinaaRmdego vaqcinacia unda CautardeT imunosupresirebuli pirebis ojaxis wevrebsac, Tu maT ar aReniSnebaT winaaRmdegCvenebebi. rekomendacia • yviTeli cxelebis vaqcina ar unda iqnas gamoyenebuli aiv inficirebulebSi, rogorc bavSvebSi, aseve zrdasrulebSi, imunodeficitis statusis miuxedavad, garda im SemTxvevebisa, rodesac mosalodneli dadebiTi Sedegi aWarbebs arsebul risks (DIV). 115
- Page 64 and 65: saerTaSoriso saxeli stavudini (d4T)
- Page 66 and 67: mcire mutacia muSaobs kombinaciaSi.
- Page 68 and 69: 25. Phillips AN et al. Viral load o
- Page 70 and 71: Suppl 2:S171-176. 73. Altice FL, Mo
- Page 72 and 73: 122. Koval CE et al. Immune reconst
- Page 74 and 75: kandidozi dRe yovel dRe - ko-trimoq
- Page 76 and 77: karcinoma (ara SidsTan perikardiuli
- Page 78 and 79: o cxeleba o wonaSi kleba o Ramis of
- Page 80 and 81: indikatorebi filtvis darRveuli funq
- Page 82 and 83: o yvelaze xSirad viTardeba diarea,
- Page 84 and 85: o glukokortikoidebis sistematiuri m
- Page 86 and 87: 100 mg/dReSi meore rigis sqemebi am
- Page 88 and 89: o eqspoziciis Sedegad daavadebis ga
- Page 90 and 91: o remisiis miRweva Zalian Znelia da
- Page 92 and 93: qimioTerapiiT (mag : B-ALL reJimi)
- Page 94 and 95: • imunodeficitis mqone pacientebS
- Page 96 and 97: an famcikloviri 500 mg 3-jer dReSi
- Page 98 and 99: • berkitis-tipis limfoma; • naz
- Page 100 and 101: 3.2.2. cxeleba aiv inficirebulebSi
- Page 102 and 103: afTozuri wylulebi stomatiti qeiliti
- Page 104 and 105: ganmavlobaSi 2 Tvis manZilze (xelis
- Page 106 and 107: o gamonayari warmodgenilia mravlobi
- Page 108 and 109: 20. Chen XM et al. Cryptosporidiosi
- Page 110 and 111: Tavi IV. aiv infeqcia/SidsiT daavad
- Page 112 and 113: inficirebul bavSvebSi (ramdenadac a
- Page 116 and 117: 4.3. daxocili da inaqtivirebuli vaq
- Page 118 and 119: kerebSi A hepatiti erTeuli an mcire
- Page 120 and 121: 13 riski maRalia staJirebis periodS
- Page 122 and 123: ganmavlobaSi, xolo SedarebiT ufro s
- Page 124 and 125: 4.8. tkipismieri encefalitis vaqcin
- Page 126 and 127: CvenebebiTa da doziT, rogorc imunok
- Page 128 and 129: 4.11.2.3. cofis sawinaaRmdego imuno
- Page 130 and 131: ekomendebulia: vaqcina rekomendebul
- Page 132 and 133: 8. United States Centers for Diseas
- Page 134 and 135: aiv infeqcia/Sidsis antiretrovirusu
- Page 136 and 137: 5. mkurnaloba a) rekomendebuli pirv
- Page 138 and 139: aiv infeqcia/SidsiT daavadebuli bav
- Page 140 and 141: joxiseburi TiTebi. Tumca wlebis man
- Page 142 and 143: * saWiroa arv preparatebis bavSvebi
- Page 144 and 145: laboratoriuli monacemebis kontroli
- Page 146 and 147: Tirkmlis funqciuri sinjebi, gulmker
- Page 148 and 149: aiv infeqcia/Sidsis fonze ganviTare
- Page 150 and 151: aiv infeqcia/Sidsis fonze ganviTare
- Page 152 and 153: 6. reabilitacia da dakvirveba monit
- Page 154 and 155: kandidozuri ezofagitis SemTxvevebSi
- Page 156 and 157: aiv infeqcia/Sidsis fonze ganviTare
- Page 158 and 159: aiv infeqcia/Sidsis fonze ganviTare
- Page 160 and 161: aiv infeqcia/Sidsis fonze ganviTare
- Page 162 and 163: aiv infeqcia/Sidsis fonze ganviTare
omlebsac ar ga<strong>da</strong>utaniaT Cutyvavila (pirveladi <strong>infeqcia</strong>), aReniSnebaT<br />
zosteri (rekurentuli <strong>infeqcia</strong>) an arian seronegatiurni _ sasurvelia<br />
moeridon eqspozicias CutyvaviliT an zosteriT <strong>da</strong>avadebul pirebTan.<br />
<strong>aiv</strong> inficirebul/<strong>SidsiT</strong> <strong>da</strong>avadebulebTan mWidro kontaqtSi myof pirebs<br />
(gansakuTrebiT bavSvebs), romlebsac ar ga<strong>da</strong>utaniaT Cutyvavila <strong>da</strong> arian<br />
<strong>aiv</strong> seronegatiurebi, un<strong>da</strong> CautardeT Cutyvavilas vaqcinacia, raTa ar<br />
moxdes virusis transmisia am pirebi<strong>da</strong>n im <strong>aiv</strong> inficirebulebze,<br />
romlebic Cutyvavila-zosteris virusis mimarT maRali mimReblobiT<br />
gamoirCevian.<br />
rekomen<strong>da</strong>ciebi<br />
• Cutyvavilas vaqcina ar un<strong>da</strong> iqnas gamoyenebuli <strong>aiv</strong> inficirebul<br />
mozrdilebSi imunodeficitis statusis miuxe<strong>da</strong>vad, aseve <strong>aiv</strong><br />
inficirebul bavSvebSi zomieri an mZime imunosupresiiT.<br />
• Cutyvavilas vaqcina un<strong>da</strong> gamoviyenoT mxolod asimptomur <strong>da</strong> msubuqad<br />
gamoxatuli simptomatikis mqone <strong>aiv</strong> inficirebul bavSvebSi (CD4>=25%)<br />
(BII).<br />
• <strong>aiv</strong> inficirebul/<strong>SidsiT</strong> <strong>da</strong>avadebulebTan mWidro kontaqtSi myof<br />
pirebs, romlebic gamoirCevian virusis mimarT maRali mimReblobiT,<br />
un<strong>da</strong> CautardeT vaqcinacia Cutyvavila-zosteris virusis SesaZlo<br />
transmisiis prevenciis mizniT.<br />
4.2.8. yviTeli cxelebis vaqcina<br />
yviTeli cxelebis vaqcinis virusi Teoriulad warmoadgens encefalitis<br />
ganviTarebis risk-faqtors <strong>aiv</strong> inficirebul pirebSi, ris gamoc is<br />
aRniSnul kategoriaSi ar gamoiyeneba. yviTeli cxeleba endemuri<br />
<strong>da</strong>avadebaa ekvatoruli afrikis 33 <strong>da</strong> samxreT amerikis 11 qveyanaSi.<br />
aRniSnul teriatoriaze mogzaurobisas mkurnalma eqimma pacients un<strong>da</strong><br />
miawodos informacia arsebuli riskisa <strong>da</strong> moskitebisagan Tav<strong>da</strong>cvis<br />
meTodebis Sesaxeb. zogierTi klinika pirovnebis CD4+ ujredebis ricxvis<br />
gaTvaliswinebiT iRebs vaqcinaciis ga<strong>da</strong>wyvetilebas.<br />
Tu <strong>aiv</strong> inficirebuli piri ver aridebs Tavs yviTeli cxelebis virusTan<br />
potenciur eqspozicias mas un<strong>da</strong> SevTavazoT vaqcinacia. saWiroa<br />
vaqcinaciasTan <strong>da</strong>kavSirebuli SesaZlo gverdiTi reaqciebis monitoringi.<br />
ramdena<strong>da</strong>c <strong>aiv</strong> negatiur pirebTan Se<strong>da</strong>rebiT <strong>aiv</strong> pozitiur a<strong>da</strong>mianebSi<br />
vaqcinacia SesaZloa iyos naklebad efeqturi, sasurvelia<br />
maneitralizebeli antisxeulebis titris gansazRvra endemur keraSi<br />
mogzaurobamde. yviTeli cxelebis sawinaaRmdego vaqcinacia un<strong>da</strong><br />
CautardeT imunosupresirebuli pirebis ojaxis wevrebsac, Tu maT ar<br />
aReniSnebaT winaaRmdegCvenebebi.<br />
rekomen<strong>da</strong>cia<br />
• yviTeli cxelebis vaqcina ar un<strong>da</strong> iqnas gamoyenebuli <strong>aiv</strong><br />
inficirebulebSi, rogorc bavSvebSi, aseve zr<strong>da</strong>srulebSi,<br />
imunodeficitis statusis miuxe<strong>da</strong>vad, gar<strong>da</strong> im SemTxvevebisa, rodesac<br />
mosalodneli <strong>da</strong>debiTi Sedegi aWarbebs arsebul risks (DIV).<br />
115
Change language